1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 5 1.2 List of Figures 11 2 Introduction 12 2.1 Chronic Respiratory Disease Report Coverage 12 2.2 Asthma - Overview 12 2.3 Chronic Obstructive Pulmonary Disease (COPD) - Overview 12 2.4 Idiopathic Pulmonary Fibrosis - Overview 12 3 Therapeutics Development 13 3.1 Asthma 13 3.2 Chronic Obstructive Pulmonary Disease (COPD) 33 3.3 Idiopathic Pulmonary Fibrosis 51 4 Therapeutics Assessment 65 4.1 Asthma 65 4.2 Chronic Obstructive Pulmonary Disease (COPD) 81 4.3 Idiopathic Pulmonary Fibrosis 94 5 Companies Involved in Therapeutics Development 106 5.1 Asthma 106 5.2 Chronic Obstructive Pulmonary Disease (COPD) 172 5.3 Idiopathic Pulmonary Fibrosis 223 6 Dormant Projects 259 6.1 Asthma 259 6.2 Chronic Obstructive Pulmonary Disease (COPD) 279 6.3 Idiopathic Pulmonary Fibrosis 302 7 Discontinued Products 307 7.1 Asthma 307 7.2 Chronic Obstructive Pulmonary Disease (COPD) 311 7.3 Idiopathic Pulmonary Fibrosis 316 8 Product Development Milestones 317 8.1 Asthma 317 8.2 Chronic Obstructive Pulmonary Disease (COPD) 331 8.3 Idiopathic Pulmonary Fibrosis 345 9 Appendix 360 9.1 Methodology 360 9.2 Coverage 360 9.3 Secondary Research 360 9.4 Primary Research 360 9.5 Expert Panel Validation 360 9.6 Contact Us 360 9.7 Disclaimer 361

1.1 List of Tables Table 1: Number of Products under Development for Asthma 13 Table 2: Number of Products under Development by Companies, Asthma 15 Table 3: Number of Products under Development by Universities/Institutes, Asthma 20 Table 4: Products under Development by Companies, Asthma 21 Table 5: Products under Development by Universities/Institutes, Asthma 31 Table 6: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) 33 Table 7: Number of Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 34 Table 8: Number of Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 38 Table 9: Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 39 Table 10: Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 50 Table 11: Number of Products under Development for Idiopathic Pulmonary Fibrosis 51 Table 12: Number of Products under Development by Companies, Idiopathic Pulmonary Fibrosis 53 Table 13: Number of Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 56 Table 14: Products under Development by Companies, Idiopathic Pulmonary Fibrosis 57 Table 15: Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 64 Table 16: Number of Products by Stage and Target, Asthma 66 Table 17: Number of Products by Stage and Mechanism of Action, Asthma 72 Table 18: Number of Products by Stage and Route of Administration, Asthma 78 Table 19: Number of Products by Stage and Molecule Type, Asthma 80 Table 20: Number of Products by Stage and Target, Chronic Obstructive Pulmonary Disease (COPD) 82 Table 21: Number of Products by Stage and Mechanism of Action, Chronic Obstructive Pulmonary Disease (COPD) 87 Table 22: Number of Products by Stage and Route of Administration, Chronic Obstructive Pulmonary Disease (COPD) 92 Table 23: Number of Products by Stage and Molecule Type, Chronic Obstructive Pulmonary Disease (COPD) 93 Table 24: Number of Products by Stage and Target, Idiopathic Pulmonary Fibrosis 95 Table 25: Number of Products by Stage and Mechanism of Action, Idiopathic Pulmonary Fibrosis 99 Table 26: Number of Products by Stage and Route of Administration, Idiopathic Pulmonary Fibrosis 103 Table 27: Number of Products by Stage and Molecule Type, Idiopathic Pulmonary Fibrosis 105 Table 28: Asthma - Pipeline by 4D Pharma PLC 106 Table 29: Asthma - Pipeline by AB Science SA 106 Table 30: Asthma - Pipeline by AbbVie Inc 107 Table 31: Asthma - Pipeline by Abeome Corp 107 Table 32: Asthma - Pipeline by Accolade Pharmaceuticals LLC 108 Table 33: Asthma - Pipeline by Adamis Pharmaceuticals Corp 108 Table 34: Asthma - Pipeline by ALK-Abello AS 109 Table 35: Asthma - Pipeline by Allergan Plc 110 Table 36: Asthma - Pipeline by Allergopharma GmbH & Co KG 111 Table 37: Asthma - Pipeline by Almirall SA 111 Table 38: Asthma - Pipeline by Amgen Inc 112 Table 39: Asthma - Pipeline by Amphastar Pharmaceuticals Inc 112 Table 40: Asthma - Pipeline by AnaptysBio Inc 113 Table 41: Asthma - Pipeline by AnGes Inc 113 Table 42: Asthma - Pipeline by Antisense Therapeutics Ltd 114 Table 43: Asthma - Pipeline by Apollo Endosurgery Inc 114 Table 44: Asthma - Pipeline by ASIT Biotech SA 115 Table 45: Asthma - Pipeline by Aslan Pharmaceuticals Pte Ltd 115 Table 46: Asthma - Pipeline by Astellas Pharma Inc 116 Table 47: Asthma - Pipeline by AstraZeneca Plc 117 Table 48: Asthma - Pipeline by Aurigene Discovery Technologies Ltd 117 Table 49: Asthma - Pipeline by Biocon Ltd 118 Table 50: Asthma - Pipeline by BiosanaPharma BV 118 Table 51: Asthma - Pipeline by Biotec Pharmacon ASA 119 Table 52: Asthma - Pipeline by Boehringer Ingelheim GmbH 119 Table 53: Asthma - Pipeline by Celon Pharma SA 120 Table 54: Asthma - Pipeline by Chiesi Farmaceutici SpA 121 Table 55: Asthma - Pipeline by Crossject SA 121 Table 56: Asthma - Pipeline by CrystalGenomics Inc 122 Table 57: Asthma - Pipeline by CSL Ltd 123 Table 58: Asthma - Pipeline by CSPC Pharmaceutical Group Limited 123 Table 59: Asthma - Pipeline by Cumberland Pharmaceuticals Inc 124 Table 60: Asthma - Pipeline by Cynata Therapeutics Ltd 1241.2 List of Figures Figure 1: Number of Products under Development for Asthma 13 Figure 2: Number of Products under Development by Companies, Asthma 14 Figure 3: Number of Products under Development by Universities/Institutes, Asthma 19 Figure 4: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD 33 Figure 5: Number of Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 34 Figure 6: Number of Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 38 Figure 7: Number of Products under Development for Idiopathic Pulmonary Fibrosis 51 Figure 8: Number of Products under Development by Companies, Idiopathic Pulmonary Fibrosis 52 Figure 9: Number of Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 56 Figure 10: Number of Products by Top 10 Targets, Asthma 65 Figure 11: Number of Products by Stage and Top 10 Targets, Asthma 65 Figure 12: Number of Products by Top 10 Mechanism of Actions, Asthma 71 Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Asthma 71 Figure 14: Number of Products by Top 10 Routes of Administration, Asthma 76 Figure 15: Number of Products by Stage and Top 10 Routes of Administration, Asthma 77 Figure 16: Number of Products by Top 10 Molecule Types, Asthma 78 Figure 17: Number of Products by Stage and Top 10 Molecule Types, Asthma 79 Figure 18: Number of Products by Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD) 81 Figure 19: Number of Products by Stage and Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD) 81 Figure 20: Number of Products by Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD) 85 Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD) 86 Figure 22: Number of Products by Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD) 91 Figure 23: Number of Products by Stage and Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD) 91 Figure 24: Number of Products by Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD) 92 Figure 25: Number of Products by Stage and Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD) 93 Figure 26: Number of Products by Top 10 Targets, Idiopathic Pulmonary Fibrosis 94 Figure 27: Number of Products by Stage and Top 10 Targets, Idiopathic Pulmonary Fibrosis 94 Figure 28: Number of Products by Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis 97 Figure 29: Number of Products by Stage and Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis 98 Figure 30: Number of Products by Routes of Administration, Idiopathic Pulmonary Fibrosis 102 Figure 31: Number of Products by Stage and Routes of Administration, Idiopathic Pulmonary Fibrosis 102 Figure 32: Number of Products by Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis 103 Figure 33: Number of Products by Stage and Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis 104

4D Pharma PLC AbbVie Inc Accolade Pharmaceuticals LLC Ache Laboratorios Farmaceuticos SA AdAlta Ltd Advanced Inhalation Therapies (AIT) Ltd Aeolus Pharmaceuticals Inc AlgiPharma AS ALK-Abello AS Allergan Plc Allergopharma GmbH & Co KG Allinaire Therapeutics LLC Almirall SA Amgen Inc Amphastar Pharmaceuticals Inc Amplia Therapeutics Ltd AnaMar AB AnaptysBio Inc AnGes Inc Angiocrine Bioscience Inc Antisense Therapeutics Ltd Apollo Endosurgery Inc Aridis Pharmaceuticals Inc Asahi Kasei Corp ASIT Biotech SA Aslan Pharmaceuticals Pte Ltd Aurigene Discovery Technologies Ltd AusBio Ltd BerGenBio ASA Biocon Ltd Biogen Inc BiosanaPharma BV BioStem Technologies Inc Biotec Pharmacon ASA BreStem Therapeutics Inc Bristol-Myers Squibb Co C4X Discovery Holdings PLC Celdara Medical LLC Celgene Corp Certa Therapeutics Pty Ltd China Resources Pharmaceutical Group Ltd Chronic Obstructive Pulmonary Disease (COPD) Cipla Ltd Circassia Pharmaceuticals Plc Compugen Ltd Crossject SA CrystalGenomics Inc CSPC Pharmaceutical Group Limited Cumberland Pharmaceuticals Inc Daewoong Pharmaceutical Co Ltd Denceptor Therapeutics Ltd Denovo Biopharma LLC Diffusion Pharmaceuticals Inc Domainex Ltd Energenesis Biomedical Co Ltd Errant Gene Therapeutics LLC Evaxion Biotech ApS FibroGen Inc FibroStatin SL FLX Bio Inc Fountain Biopharma Inc Galecto Biotech AB Genentech Inc GeneScience Pharmaceuticals Co Ltd GenKyoTex SA Gilead Sciences Inc Global Blood Therapeutics Inc Gossamer Bio Inc Grifols SA Guangdong Zhongsheng Pharmaceutical Co Ltd Hanmi Pharmaceuticals Co Ltd Humanigen Inc Hydra Biosciences Inc iBio Inc iCo Therapeutics Inc Idiopathic Pulmonary Fibrosis Idorsia Pharmaceutical Ltd InKemia IUCT Group SA InMed Pharmaceuticals Inc Insmed Inc Inspyr Therapeutics Inc Inventiva Isarna Therapeutics GmbH JHL Biotech Inc Johnson & Johnson Kadmon Corp LLC Knopp Biosciences LLC Kyorin Pharmaceutical Co Ltd Laboratorios LETI SL Lead Discovery Center GmbH LG Chem Ltd LifeMax Laboratories Inc Longevity Biotech Inc Lung Therapeutics Inc Merck & Co Inc Mereo Biopharma Group Plc Meridigen Biotech Co Ltd Miragen Therapeutics Inc Mission Therapeutics Ltd Mitsubishi Tanabe Pharma Corp Moerae Matrix Inc Mycenax Biotech Inc NAL Pharmaceuticals Ltd NeoPharm Co Ltd Novo Nordisk AS Nuevolution AB Nuformix Plc Octapharma AG OliX Pharmaceuticals Inc Omeros Corp OncBioMune Pharmaceuticals Inc Ono Pharmaceutical Co Ltd Onspira Therapeutics Inc Orbis Biosciences Inc Oxagen Ltd Paradigm Biopharmaceuticals Ltd Paragen Bio Pty Ltd PharmaLundensis AB Pieris Pharmaceuticals Inc Pliant Therapeutics Inc Progenra Inc Prommune Inc Pulmagen Therapeutics LLP Pulmokine Inc Pulmotect Inc Quark Pharmaceuticals Inc Qurient Co Ltd Redx Pharma Plc Reliance Life Sciences Pvt Ltd Resolys Bio Inc Revalesio Corp ReveraGen BioPharma Inc Reviva Pharmaceuticals Inc rEVO Biologics Inc Rhizen Pharmaceuticals SA Sam-A Pharm Co Ltd Samumed LLC SATT North SAS Shionogi & Co Ltd Sorrento Therapeutics Inc Swecure AB Synairgen Plc Synermore Biologics Co Ltd Synovo GmbH Syntrix Biosystems Inc Taiho Pharmaceutical Co Ltd TaiwanJ Pharmaceuticals Co Ltd Telocyte LLC Teva Pharmaceutical Industries Ltd The Geneva Biotech Center SA United BioPharma Inc Unizyme Laboratories AS Vascular BioSciences Vectura Group Plc Vicore Pharma AB WhanIn Pharmaceutical Co Ltd Xencor Inc X-Rx Inc Yuhan Corp Yungjin Pharm Co Ltd